Fosun Pharma Unit Gets China Acceptance for Lung Cancer Drug Application
MT Newswires Live01-08
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said the resubmitted drug registration application for the Foritinib Succinate Capsules was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The drug was developed by Shanghai Fosun Pharmaceutical (Group), a unit of the company.
The indication for the acceptance is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
